• April 2019

    Read the April 2019 newsletter to learn more about the Multi-Drug Resistant Organism (MDRO) Network site visits in accordance with the National Institutes of Health (NIH) regulatory compliance requirements. The newsletter features an update from Kim Hanson, MD, MHS, Chairperson for the Diagnostics and Devices ... Read more from this Newsletter

  • January 8, 2019

    Our January 2019 newsletter provides highlights from ARLG at IDWeek 2018TM, held October 3rd-7th in San Francisco, CA. ARLG leaders, researchers, or committee members moderated panels and presented lectures, posters, or abstracts at close to 300 sessions.

    In this issue, you can learn more about Sarah Doernberg, MD, ... Read more from this Newsletter

  • September 28, 2018

    Check out our September 2018 newsletter for our latest fact sheets and lay summaries of results for the RADICAL and PROOF studies.

    In this issue, we interview Yohei Doi, MD, PhD, chair of the Gram-negative Committee who provides his thoughts and insights on contributions to date and
    Read more from this Newsletter

  • June 27, 2018

    The June 2018 newsletter features highlights from our Multi-Drug Resistance Organism (MDRO) global network meeting in Madrid, Spain, as well as an update from the ARLG Mentoring Program.

    We also profile ARLG Research Fellow Judith Anesi, MD, and two Early Stage Investigator Grant recipients, Michael A. ... Read more from this Newsletter

  • March 29, 2018

    Our March 2018 newsletter shares updates from the 2018 ARLG Operations Retreat, as well as highlights the ARLG Special Populations Special Emphasis Panel and the Pediatrics Subcommittee.

    You can also learn more about Ritu Banerjee, MD, PhD, who along with other ARLG investigators developed the Rapid Identification ... Read more from this Newsletter


With the ARLG newsletter, you will receive important updates regarding recent events, grants, publications, and the committees that help us work toward our mission: to prioritize, design, and execute clinical research that will reduce the public health threat of antibacterial resistance. If you are not receiving the ARLG newsletter, you can subscribe to stay connected and to make sure you are receiving the latest updates.

Read past issues of our newsletter by clicking the links below: